Literature DB >> 12752347

Rabeprazole is superior to omeprazole for the inhibition of peptone meal-stimulated gastric acid secretion in Helicobacter pylori-negative subjects.

G V Ohning1, J H Walsh, J R Pisegna, A Murthy, J Barth, T O G Kovacs.   

Abstract

BACKGROUND: Peptone meal-stimulated gastric acid output is considered to be a reliable means to evaluate drug-mediated inhibition of stimulated gastric acid output, an important measure of the efficacy of the agents--such as proton pump inhibitors--used to treat acid-related disorders. AIM: To compare the initial and overall inhibitory effects on peptone meal-stimulated gastric acid secretion of rabeprazole and omeprazole, 20 mg, in Helicobacter pylori-negative subjects on the first and eighth days of treatment.
METHODS: Healthy volunteers (n = 27) were randomized in a single-centre, double-blind, double-dummy, 2 x 2 cross-over study. Subjects received an oral dose of rabeprazole or omeprazole, 20 mg once daily, for 8 days. After a 2-4-week washout period, subjects were crossed over to receive the other medication for 8 days. Peptone meal-stimulated gastric acid secretion was measured at hours 11 and 23 at baseline and on days 1 and 8 of treatment.
RESULTS: On days 1 and 8, rabeprazole demonstrated a significantly greater inhibition of peptone meal-stimulated gastric acid secretion compared with omeprazole at all time points (P < 0.03). Median values of steady-state inhibition on day 1 were statistically significant at hour 23 (rabeprazole 100% vs. omeprazole 74%, P < 0.02).
CONCLUSIONS: Rabeprazole, 20 mg, demonstrated superior control of peptone meal-stimulated gastric acid secretion compared with omeprazole, 20 mg, after the first dose and after the eighth daily dose. Rabeprazole achieved a more rapid onset of acid inhibition and a greater steady-state reduction in peptone meal-stimulated gastric acid secretion.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12752347      PMCID: PMC6736539          DOI: 10.1046/j.1365-2036.2003.01573.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  13 in total

1.  Dose-response study of omeprazole on meal-stimulated gastric acid secretion and gastrin release.

Authors:  W Londong; V Londong; C Cederberg; H Steffen
Journal:  Gastroenterology       Date:  1983-12       Impact factor: 22.682

Review 2.  Review article: the pharmacology of rabeprazole.

Authors:  M P Williams; R E Pounder
Journal:  Aliment Pharmacol Ther       Date:  1999-08       Impact factor: 8.171

3.  Rabeprazole produces rapid, potent, and long-acting inhibition of gastric acid secretion in subjects with Helicobacter pylori infection.

Authors:  G V Ohning; R C Barbuti; T O Kovacs; B Sytnik; T J Humphries; J H Walsh
Journal:  Aliment Pharmacol Ther       Date:  2000-06       Impact factor: 8.171

4.  A placebo-controlled study to assess the effects of 7-day dosing with 10, 20 and 40 mg rabeprazole on 24-h intragastric acidity and plasma gastrin in healthy male subjects.

Authors:  M P Williams; C Blanshard; C Millson; J Sercombe; R E Pounder
Journal:  Aliment Pharmacol Ther       Date:  2000-06       Impact factor: 8.171

Review 5.  The benefit/risk profile of rabeprazole, a new proton-pump inhibitor.

Authors:  D Johnson; C Perdomo; J Barth; L Jokubaitis
Journal:  Eur J Gastroenterol Hepatol       Date:  2000-07       Impact factor: 2.566

6.  Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study.

Authors:  C P Dekkers; J A Beker; B Thjodleifsson; A Gabryelewicz; N E Bell; T J Humphries
Journal:  Aliment Pharmacol Ther       Date:  1999-02       Impact factor: 8.171

7.  Integrated acidity and rabeprazole pharmacology.

Authors:  J D Gardner; C Perdomo; S Sloan; W F Hahne; J A Barth; S Rodriguez-Stanley; M Robinson
Journal:  Aliment Pharmacol Ther       Date:  2002-03       Impact factor: 8.171

8.  Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity.

Authors:  B K Sharma; R P Walt; R E Pounder; M D Gomes; E C Wood; L H Logan
Journal:  Gut       Date:  1984-09       Impact factor: 23.059

9.  Glucose perfusion intragastric titration.

Authors:  V Maxwell; V E Eysselein; J Kleibeuker; T Reedy; J H Walsh
Journal:  Dig Dis Sci       Date:  1984-04       Impact factor: 3.199

10.  Gastric acid secretion rate and buffer content of the stomach after eating. Results in normal subjects and in patients with duodenal ulcer.

Authors:  J S Fordtran; J H Walsh
Journal:  J Clin Invest       Date:  1973-03       Impact factor: 14.808

View more
  7 in total

1.  Comparative efficacy of rabeprazole and pantoprazole in the control of nocturnal Acid output and intragastric acidity.

Authors:  Hank S Wang; David S Oh; Ariana Anderson; Jose Nieto; Phuong Tien; Gordon Ohning; Joseph R Pisegna
Journal:  Gut Liver       Date:  2008-06-30       Impact factor: 4.519

Review 2.  Proton pump inhibitors: an update of their clinical use and pharmacokinetics.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2008-08-05       Impact factor: 2.953

Review 3.  Rabeprazole: an update of its use in acid-related disorders.

Authors:  C I Carswell; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Rabeprazole controls GERD symptoms in a patient for whom treatment with lansoprazole failed: first report of "cluster GERD.".

Authors:  David S Oh; Gordon V Ohning; Joseph R Pisegna
Journal:  Dig Dis Sci       Date:  2005-05       Impact factor: 3.199

5.  Rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease: A comparative study of efficacy and safety.

Authors:  Rituparna Maiti; Jyothirmai Jaida; P L John Israel; Narendar Koyagura; Sruthi Mukkisa; Anuradha Palani
Journal:  J Pharmacol Pharmacother       Date:  2011-07

6.  A review of rabeprazole in the treatment of acid-related diseases.

Authors:  Fabio Pace; Stefano Pallotta; Stefania Casalini; Gabriele Bianchi Porro
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

7.  Mucosal Healing Effectiveness and Safety of Anaprazole, a Novel PPI, vs. Rabeprazole in Patients With Duodenal Ulcers: A Randomized Double-Blinded Multicenter Phase II Clinical Trial.

Authors:  Xu Shu; Zhenhua Zhu; Yu Fu; Zhenyu Zhang; Jiangbin Wang; Xing Li; Shuixiang He; Huizhen Fan; Side Liu; Guoxin Zhang; Jianhua Tang; Caibin Huang; Qin Du; Xiaoyan Wang; Baohong Xu; Yiqi Du; Qikui Chen; Bangmao Wang; Ying Chen; Xianghui Duan; Yong Xie; Lijuan Huo; Xiaohua Hou; Nonghua Lu
Journal:  Front Med (Lausanne)       Date:  2021-07-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.